- Products
- CytoCloud
Cloud-based Karyotype analysis
AI KaryotypeScanner agnostic karyotyping application
Pioneering AutomatedCell Imaging Since 2000
BioView develops, manufactures and markets innovative automated cell imaging and analysis solutions for cytology, cytogenetic, pathology clinical and research laboratories worldwide.
A quarter century of automated imaging breakthroughs.
BioView develops, manufactures and markets innovative automated cell imaging and analysis solutions for cytology, cytogenetic, pathology clinical and research laboratories.
Operating since 2000, BioView is headquartered in Israel and has a fully owned subsidiary in the United States responsible for sales and support in the Americas. Products are also internationally distributed by leading partners.
Founded and managed by experts, BioView leverages deep experience in medical devices combined with clinical and research applications to create breakthrough imaging and analysis solutionsת staying one step ahead with assay-specific applications ready for use before the tests reach the market.
Built on deep expertise.
Scanning equipment and imaging algorithms tested and validated by world-leading institutes, proven to meet the requirements of both research and clinical laboratories.
Technological Excellence
Proprietary imaging, analysis, and review technology that automatically controls fully motorized fluorescent and bright-field microscopes equipped with high-resolution cameras. reducing turnaround time on labor-intensive tests.
FDA Clearance & Approvals
Our DUET imaging and analysis platform is FDA-cleared for multiple FISH applications. BioView products carry CE marking and approvals from Korean, Australian and Thai FDAs, and we keep expanding.
Global Reach
Headquartered in Israel with a fully-owned US subsidiary handling sales and support across the Americas. Products are internationally distributed by leading partners.
Clinical & Research Expertise
Founded and led by experts in medical devices, vision applications and laboratory workflows, delivering assay-specific applications ready for use before tests reach the market.
Milestones that shaped BioView.
- 2000
BioView founded in Israel by a team of biologists, physicists and software engineers.
- 2005
DUET platform validated by leading institutes for FISH-based cancer diagnostics.
- 2012
FDA clearance secured for multiple FISH applications on the DUET platform.
- 2018
Global distribution expanded.
- 2020
Next generation products launched, expanding the BioView portfolio.
- Today
Powering automated cell imaging in clinical and research labs across 40+ countries.
Transparent reporting. Long-term value.
BioView is publicly traded on the Tel Aviv Stock Exchange. Access our latest financial statements, periodic reports and capital market presentations.
Have a question? We're here to help.
Reach out to our team and we'll get back to you within one business day.